rently employed and identify opportunities for future research. METHODS: A comprehensive literature review of reference databases, conference abstracts, journals and medical societies' websites was performed. Publications reporting practice management efficiency measures within ambulatory oncology practices and infusion centers located in the United States were included. Search was limited to English-language articles published between 2007 and 2010. All publication types except continuing medical education materials and letters to the editor were accepted. Evidence quality was assessed with the Completeness of Reporting index (CORE-14) instrument. RESULTS: Forty-seven references were accepted for inclusion. Efficiency strategies were classified into 7 distinct categories, each reported at a similar frequency in the literature. Within and across these categories, common themes were standardization of care, use of best practices, and alignment between quality and profitability initiatives. Most publications were recommendations without a study design type (64%) and/or did not report quantifiable outcome data (74%). Additionally, 21 publications did not define the practice type included, while the remaining articles identified 12 different practice types. Consequently, applicability is limited, since outcomes cannot be associated with a particular practice type. Thirty-four publications were assigned a CORE-14 score of 0, indicating they did not meet any criteria for methodological quality (mean score, 1.84). CONCLUSIONS: Numerous efficiency methods are being touted in the literature, but there is limited definitive data on the successfulness of these techniques. Further research, of a high methodological caliber, is needed to support informed decisions. Specifically, registries, surveys, and economic analyses would empower oncologists and other oncology professionals with practical strategies to concurrently improve quality while maintaining profitability. 
OBJECTIVES:
After failing approved treatments, patients may receive investigational therapies through participation in a clinical trial or an expanded access program (EAP). EAPs were established after the FDA decided to allow patients access to investigational drugs for treatment purposes, and since then EAPs have been set up in various therapeutic areas including oncology and infectious diseases. No analysis, however, has been completed evaluating the use and value of EAP data to US payers. METHODS: We analyzed the impact of EAP data on the US payer decision making process in drug formulary positioning. Using examples of different types of drug data including EAP, payers were asked how each type affected drug coverage. After reviewing these results, we assessed payers' awareness of EAP relative to other data types to determine future impacts of EAP. Our study allowed us to define the key value drivers for EAP trials and construct a value matrix to evaluate future EAP opportunities. RESULTS: Payers in the United States had a low awareness of EAP data driven by a lack of exposure to the data type but mostly attributed to their sole use of RCT data in formulary decisions. While most payers agreed that EAP data has little influence on their decision making process, they did highlight factors that make EAP data more valuable to other stakeholders and discussed how EAP data could improve product perception. CONCLUSIONS: Our findings suggest that payers will not change their management approach and formulary decisions based on EAP data. Payers realize that EAP data might be more representative of the real world patient population than data from RCTs; however, RCTs will remain the gold standard data source to evaluate agents for reimbursement and formulary placement.
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PGI1 INCIDENCE OF ANEMIA AND NEUTROPENIA FOLLOWING HCV TREATMENT INITIATION AND RELATED DRUG TREATMENT COSTS IN THE UNITED STATES
Diels J, Gavart S, Nuyts G Janssen Pharmaceutica, Beerse, Belgium OBJECTIVES: Conventional peginterferon-ribavirin antiviral treatment of chronic hepatitis C virus (HCV) often leads to anemia and neutropenia. Based on US claims data, we explored the incidence of both adverse events (AEs) and the associated risk factors, and assessed the related erythropoietin/granulocyte colony stimulating factor (G-CSF) costs in daily clinical practice. METHODS: Commercially insured patients with chronic HCV infection (ICD9 070.44, 070.54, 070.70, 070 .71) (all genotypes), who initiated any combination of (peg)interferon and/or ribavirin were identified in a large US claims database (Thomson 2006 (Thomson -2009 . Time to first onset of anemia and neutropenia was analyzed using Kaplan-Meier and Cox proportional hazards regression. Anemia and neutropenia were defined based on ICD9-coding (280-285,288) and/or prescription of erythropoietin and G-CSF. RESULTS: 3,935 chronic HCV-infected patients (mean age 51.1, 63% male) initiated HCV treatment. 86% of the patients initiated a combination of peginterferon and ribavirin. Mean treatment duration was 245 days. Regardless of time on treatment, 32%/17% of the cohort experienced anemia/neutropenia respectively. Age, female gender, Charlson co-morbidity index and liver cirrhosis were predictive for both AEs. 20.3%/ 11.3% of the cohort received erythropoietin/G-CSF treatment respectively, on average for 131/126 days. The mean cost for the entire cohort to manage both AEs was $2,263 (erythropoietin) and $1,004 (G-CSF), which represents 12% of the overall healthcare cost in the follow-up year for the entire cohort. The majority of the costs associated with AE-related treatments (58%/54%) occurred after week 24 of therapy. CONCLUSIONS: Costs of managing anemia and neutropenia during HCV treatment are considerable and often continued beyond 24 weeks of treatment.
New HCV treatment combinations allowing to shorten treatment up to 24 weeks, may considerably reduce AE-related costs. This reduction may be most important in treatment-naive genotype 1-infected patients, as the standard 48-week treatment duration is longer compared with other genotypes. 
PGI2 PREDICTORS OF PROTON PUMP INHIBITOR (PPI) DOSING REGIMEN AMONG PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Eisenberg
